It has 24 dosage forms, more than 2000 kinds of medicines and health products. Through secondary development, more than a dozen varieties have been cultivated, such as Ning Fei, Xiaomi Suppository, Liuwei Dihuang, Jingyaokang, Yiqi Yangxue and so on. Using new preparation technology, Starshu pellets and dispersible tablets were developed, which ensured the position of correction liquid in the domestic stomach medicine market.
Extended data
It has a domestic scientific research system integrating scientific and technological management, innovative drug research and the transformation of new technological achievements. It has more than 300 technical experts from China, obtained more than 700 authorized patents and won 7 national scientific and technological progress awards. There are nationally recognized enterprise technology centers, national engineering laboratories for quality control technology of traditional Chinese medicine, postdoctoral research centers and key engineering laboratories for standardization of traditional Chinese medicine.
The Science and Technology Innovation Center of the Group has six research institutes, including Beijing Revised New Drug Research Institute, Revised Biomedicine (Hangzhou) Research Institute and Beijing Medicinal Diet Research Institute. The group invests about 654.38 billion yuan in scientific research every year. A new biopharmaceutical-recombinant urate oxidase for injection will be put into production soon. It is the second company in the world to produce this product after Sanofi.
Revised Pharmaceutical Group-Group Profile